Rezolute, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rezolute, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-109.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 84% of Healthcare companies in United States.
Cash Cushion Ratio
+45%Cash, after subtracting all debt, equals 45% of its market value (net cash).
Higher than 76% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Rezolute, Inc. made a loss over the last year. Rezolute, Inc. owes $0.07 for every $1 it owns. Rezolute, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Jun 2025.
P/E ratio
LossRezolute, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.20The share price is 3.20 times Rezolute, Inc.'s book value per share, higher than 58% of Healthcare companies in United States.
Market cap
$373 MThe total market value of all of Rezolute, Inc.'s shares at today's price (share price × number of shares), larger than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$117 MWhat Rezolute, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$1.21Net worth divided by the number of shares. The share price of $3.86 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
-59.0%Rezolute, Inc. lost 59.0% of its shareholders' money over the last year, lower than 56% of Healthcare companies in United States.
Owes vs Owns
0.07×Rezolute, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Dividend yield
NoneRezolute, Inc. does not currently pay a dividend.
Profit growth
LossRezolute, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashRezolute, Inc. held $166 M more cash than debt (net cash) at Jun 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rezolute, Inc.: $373 M ÷ $117 M (31 Mar 2026) = 3.2.
What is Rezolute, Inc.'s return on equity?
Rezolute, Inc. lost 59.0% of its shareholders' money over the last year, lower than 56% of Healthcare companies in United States.
How much does Rezolute, Inc. owe compared with what it owns?
Rezolute, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Does Rezolute, Inc. pay a dividend?
No. Rezolute, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.